 |
answer text |
<p>NHS England has advised that it is considering extending the current interim commissioning
policy for Sofosbuvir plus ledipasvir (Harvoni) and another direct acting antiviral
combination therapy for selected patients with cirrhosis associated with hepatitis
C. The Department is not involved in this decision.</p><p> </p><p> </p><p> </p><p>NHS
England has completed the evidence review and finalised its draft proposals. In doing
so, it has engaged with clinical and patient stakeholders from the national lead Clinical
Reference Group. NHS England has advised that the aim is that interim commissioning
policies will be in place by the first half of 2015.</p><p> </p><p> </p><p> </p><p>
</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p>
|
 |
